Intubation at TOFC=1 for Intubation (procedure)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Intubation (procedure)
Endotracheal Intubation at TOFC=1 - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this research is to learn about the difference in the endotracheal intubation condition (ease of using a device to view vocal cords, position of vocal cords, and patient's reaction to endotracheal tube insertion) and determining the appropriate time to perform the intubation.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Intubation (procedure)

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Approximately 15 mins after intubation

Approximately 15 mins after intubation
Assessment of the intubating conditions

Trial Safety

Safety Progress

1 of 3

Other trials for Intubation (procedure)

Trial Design

2 Treatment Groups

Intubation 2 minutes after rocuronium administration
1 of 2
Intubation at TOFC=1
1 of 2
Active Control
Experimental Treatment

170 Total Participants · 2 Treatment Groups

Primary Treatment: Intubation at TOFC=1 · No Placebo Group · N/A

Intubation at TOFC=1
Procedure
Experimental Group · 1 Intervention: Endotracheal Intubation at TOFC=1 · Intervention Types: Procedure
Intubation 2 minutes after rocuronium administration
Procedure
ActiveComparator Group · 1 Intervention: Endotracheal Intubation 2 minutes after rocuronium administration · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: approximately 15 mins after intubation

Who is running the clinical trial?

Mayo ClinicLead Sponsor
2,891 Previous Clinical Trials
3,698,237 Total Patients Enrolled
J. Ross Renew, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
130 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patients undergoing elective surgical procedures that require use of NMBA agents (rocuronium) administered intraoperatively.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: October 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.